Navigation Links
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
Date:6/24/2009

Preliminary top-line results of second Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study

PALO ALTO, Calif., and BRUSSELS, June 24 /PRNewswire-FirstCall/ -- press release, regulated information -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled trial of sodium oxybate to treat fibromyalgia achieved its key endpoints. As in the first randomized, double-blind fibromyalgia study, sodium oxybate significantly decreased pain and fatigue and improved daily function and patient global impression of change. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.

"Fibromyalgia is a chronic illness, characterized by widespread pain, unrefreshing sleep, chronic fatigue, and psychological distress," said I. Jon Russell, M.D., Ph.D., lead investigator in the first Phase III study and Associate Professor of Medicine, Division of Clinical Immunology and Rheumatology, and Director, University Clinical Research Center, University of Texas Health Science Center at San Antonio. "Sodium oxybate has shown a positive effect on a number of the symptoms of fibromyalgia, and thus could have a significant impact on patients' quality of life."

The second 14-week Phase III trial, conducted in the United States and seven European countries, included 573 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/nigh
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.; UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
2. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
3. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
4. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
5. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
6. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
7. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
8. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
9. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
10. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
11. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
... G rowth factor enhances ... stem cells , , BOSTON, July ... Boston have now laid the groundwork for regenerating heart tissue after a heart ... In the July 24 issue of Cell , they show that a ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
(Date:9/17/2014)... New York, N.Y. (PRWEB) September 17, 2014 ... for fans taking part in the fitness industry’s most ... in Las Vegas, NV. Two fans will each take ... fully loaded with Neon Sport supplements and gear. Fitmark ... booth during the Olympia Expo, September 19-20th. , ...
(Date:9/17/2014)... September 17, 2014 According to ... ), the leading global authority in medical device ... and regeneration market is expected to exceed ... into breast reconstruction, hernia repair, dural repair, vaginal ... and dental soft tissue regeneration. , Approximately ...
(Date:9/17/2014)... Kamut International is pleased to announce ... in Michael Angelo’s new “Made With Organic” ready-made, frozen ... lasagna ready made, frozen meal. Michael Angelo’s products feature ... new products align well with Kamut International’s mission to ... wheat must be grown certified organic. , The new ...
(Date:9/17/2014)... PA (PRWEB) September 17, 2014 ... and increase efficiency. Today, Pharmacy Healthcare Solutions, a ... a web-based analysis and forecasting tool that enables ... maximizing the impact of medications on improved patient ... Reporting uses pharmacy purchase data to identify areas ...
(Date:9/17/2014)... HealthDay Reporter , TUESDAY, ... Americans dying from accidental overdoses of narcotic painkillers jumped ... Tuesday. Deaths from overdoses of drugs such as ... per 100,000 people to 5.4 per 100,000, according ... That means about 3,000 people died in 1999 ...
Breaking Medicine News(10 mins):Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 3Health News:Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC 2Health News:Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC 3
... ... for Haiti,s Earthquake Victims, New Campaign Seeks Participants in Healing Service for Chile on ... ... and Master Zhi Gang Sha and the Institute of Soul Healing and Enlightenment, shortly after ...
... ... ... ... ...
... ... ... , ... , , ...
... ... ... ... ...
... of the major cancers in Northeast Thailand. This cancer ... mortality rates. Overexpression of Met, a hepatocyte growth factor ... is correlated with progression of this type of cancer. ... cell scattering, invasion and proliferation. Although a number of ...
... to see the human brain at work, a new generation ... appeal while it is still being designed, according to a ... University. So-called "neuromarketing" takes the tools of modern brain ... somewhat abstract likes and dislikes of customer decision-making. Though ...
Cached Medicine News:Health News:Master Zhi Gang Sha Dedicates Soul Healing Blessings for Humanity Service to Chile's Earthquake Victims 2Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 2Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 3Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 4Health News:New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 2Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 3Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 4Health News:Community Pharmacists Rise to Meet Winter Weather Challenges, Survey Finds 5Health News:Different signaling pathways of cholangiocarcinoma 2
... The ThromCat™ System is the first thrombectomy ... strength and simplicity for the full range ... Heliflex™ technology, the new ThromCat™ System flushes, ... of 700 mmHg and incorporates advanced vessel-wall ...
... telescoping plate design integrates the ... and vertebral column spacer. This ... need for supplemental fixation while ... bone graft to be delivered ...
... Tendril ST leads are ... leads, designed to bring ... and flexibility to you ... pre-formed "J leads are ...
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
Medicine Products: